Iconovo will develop a dry powder formulation and a DPI for Phase 1 studies for Swedish respiratory drug company Respiratorius AB on a fee for service basis in a deal worth up to SEK 3 million, the company said. The project, which involves development of Respiratorius’s RES030-085 for the treatment of COPD and severe asthma, would lead to a license agreement if successful. RES030-085 is part of Respiratorius’s RESP9000 series of candidates.
The announcement comes shortly after Iconovo announced the launch of its new pharma division, Iconovo Pharma, and the expansion of its deal with Amneal for a generic version of Symbicort. The company also recently announced the launch of a new DPI device, a generic version of the Ellipta inhaler called the ICOpre, at RDD 2021.
Respiratorius CEO Johan Drott said, “Starting a Phase 1 study is an important goal for Respiratorius. We are pleased to partner with Iconovo’s inhalation experts to develop an appropriate formulation and inhaler for our substance.”
Iconovo CEO Johan Wäborg commented, “The collaboration with Respiratorius further strengthens our position in the strategic area of innovative inhalation projects. We look forward to working together to reach the market in as short a time as possible.”
Read the Iconovo press release.
